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Abstract
Background: Friedreich ataxia is a neurodegenerative disease caused by the lack of frataxin, a mitochondrial protein. We
previously demonstrated that frataxin interacts with complex II subunits of the electronic transport chain (ETC) and putative
electronic transfer flavoproteins, suggesting that frataxin could participate in the oxidative phosphorylation.
Methods and Findings: Here we have investigated the effect of riboflavin and its cofactors flavin adenine dinucleotide
(FAD) and flavin mononucleotide (FMN) in Saccharomyces cerevisiae and Caenorhabditis elegans models of frataxin
deficiency. We used a S. cerevisiae strain deleted for the yfh1 gene obtained by homologous recombination and we assessed
growth in fermentable and non-fermentable cultures supplemented with either riboflavin or its derivates. Experiments with
C. elegans were performed in transient knock-down worms (frh-1[RNAi]) generated by microinjection of dsRNA frh-1 into the
gonads of young worms. We observed that FAD rescues the phenotype of both defective organisms. We show that cell
growth and enzymatic activities of the ETC complexes and ATP production of yfh1D cells were improved by FAD
supplementation. Moreover, FAD also improved lifespan and other physiological parameters in the C. elegans knock-down
model for frataxin.
Conclusions/Significance: We propose that rescue of frataxin deficiency by FAD supplementation could be explained by an
improvement in mitochondrial respiration. We suggest that riboflavin may be useful in the treatment of Friedreich ataxia.
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Introduction
Friedreich ataxia (FRDA) is an autosomal recessive neurode-
generative disorder characterized by early onset and progressive
limb and gait ataxia, dysarthria, deep tendon areflexia especially of
the lower extremities, and presence of a sensory axonal
neuropathy with motor conduction velocities greater than
40 m/s. In addition, most patients show hypertrophic cardiomy-
opathy. Additional non-neurological features are skeletal deformi-
ties and glucose intolerance or diabetes mellitus [1,2]. The disease
is caused by GAA triplet expansions [3] and point mutations [4,5]
in the FXN gene mapped to human chromosome 9q13. FXN
encodes frataxin, a small protein of 210 amino acids expressed in
the mitochondrial matrix [6–8]. Frataxin seems to act as a iron
donor to other proteins for their utilization in different
biochemical pathways, such as biogenesis of iron-sulfur clusters
(ISC) [9–11] and activation of aconitase [12]. Thus, the
pathogenic consequences of frataxin deficiency have been related
with defects of ISC biogenesis but also with iron deposits [13],
oxidative stress [8] and regulation of the mitochondrial respiratory
chain [14,15].
Based on cell and mitochondrial effects of the lack of frataxin,
several pharmacological approaches have been proposed. These
include the use of antioxidants to reduce radical oxidative species.
Idebenone is a synthetic analogue of ubiquinone or coenzyme Q10
(CoQ), which has antioxidant activity and is able to act in
situations of low concentrations of oxygen. It has the ability to
inhibit the lipidic peroxidation, protecting the cellular membranes
and the mitochondria from oxidative damage. It is able to
stimulate the mitochondrial functions and increase the energetic
contribution to the myocardium. A number of clinical trials have
been conducted, suggesting a protecting effect on the cardiac
hypertrophy [16–21]. More recently, some beneficial effects of
idebenone on the neurological symptoms have also been described
[22,23]. Mitoquinone (MitoQ) is another proposed CoQ deriva-
tive with antioxidant activity selectively directed to the mitochon-
dria [24,25].
Alternative pharmacological strategies have been used. Iron
chelators mobilize the iron deposits observed in patients [26].
Chelator treatment with deferiprone causes no apparent hemato-
logic or neurologic side effects while reducing neuropathy and
ataxic gait in the youngest patients [27].
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Expansion of the GAA trinucleotide reduces transcription of
FXN gene, which in turn leads to frataxin deficiency. To reverse
FXN silencing, a class of histone deacetylase (HDAC) inhibitors
have been proposed as an alternative therapy [28–30]. Recently,
treatment of a FRDA mouse model by an HDAC inhibitor
compound has shown correction of biological parameters of
frataxin deficiency [31].
Some data suggest that frataxin may be involved in the
energetic metabolism. Clinical studies applying magnetic reso-
nance show a failure in the production of ATP in the patients’
muscles [32]. Overexpression of human frataxin in human
adipocytes increases the activity of the electron transport chain,
mitochondrial membrane potential and ATP production [14]. By
genetic and biochemical analyses in Saccharomyces cerevisiae we have
demonstrated a physical and functional interaction among the
yeast frataxin, Yfh1p, and succinate dehydrogenase subunits
Sdh1p and Sdh2p of complex II of the respiratory chain [15].
We have also confirmed the interaction among frataxin and both
SDHA and SDHB human proteins. Additionally, we also
demonstrated genetic interaction between frataxin and SDHC
subunit in Caenorhabditis elegans [33]. All these data point to a direct
role of frataxin on the complex II of the electronic transport chain
(ETC); thus, lack of frataxin may induce a failure in the oxidative
phosphorylation (OXPHOS) by means of abnormal function of
the electron transport at complex II.
Transport of electrons through the ETC is needed to correct
reduction of CoQ. In mammalian cells electrons are provided to
CoQ not just by reduction of complex I and complex II but also by
the electron transfer flavoprotein (ETF) complex, a system
composed by the ETF-dehydrogenase (ETF-QO) and ETF, a
heterodimer composed by two subunits (ETFa and ETFb), that
delivers electrons coming from b-oxidation of fatty acids and
amino acid catabolism to CoQ [34]. In S. cerevisiae b-oxidation
occurs mainly in peroxisomes but not in mitochondria; however,
homologous genes for ETF complex genes have been reported in
yeast: ypr004c as the ETFa homologue and ygr207c as the
homologue of ETFb. We have also demonstrated that Yfh1p
interacts with two of these components of the electron transfer
flavoprotein complex [15].
Human complex II is a multimeric enzyme composed of four
subunits: a flavoprotein (SDHA), an iron-sulphur subunit
(SDHB), and two proteins (SDHC and SDHD) that is anchored
to the inner mitochondrial membrane. Complex II carries
electrons to the ubiquinone pool and constitutes the second
essential oxidation–reduction reaction of the respiratory chain.
Moreover, SDHA and SDHB subunits compose the active
enzyme succinate dehydrogenase that oxidizes succinate to
fumarate in the Krebs cycle [35]. Complex II has flavin adenine
dinucleotide (FAD) as a prosthetic group that is covalently
anchored to the SDHA subunit. FAD also acts as a cofactor to the
ETF complex. FAD and flavin mononucleotide (FMN) are
cofactors derived from riboflavin, a water-soluble vitamin that
have been used in the treatment of several mitochondrial
disorders such as complex I deficiency [36], short-chain acyl
coenzyme A dehydrogenase (SCAD) [37], mitochondrial ence-
phalomyopathy with lactic acidosis and stroke-like episodes
(MELAS) syndrome [38], L-2-hydroxyglutaric aciduria [39],
and in complex II deficiency [40].
Based on our finding that frataxin interacts with subunits of the
complex II and with components of the electron transfer
flavoprotein complex we wonder whether riboflavin could be
useful in the treatment of FRDA as well. To address this question
we investigated the effect of riboflavin and riboflavin-derived
cofactors on frataxin-deficient strains of S. cerevisiae and C. elegans.
Our results show that the flavin adenin dinucleotide is able to
rescue the phenotype of both mutant organisms but, this
improvement is not dependent of complex II activity.
Results
Riboflavin-Derived Cofactors Are Able to Improve the
Growth of a Deficient yfh1D Strain
We have previously described genetic and physical interaction
among yfh1p, the yeast ortholog of mammalian FXN, and
succinate dehydrogenase complex subunits Sdh1p and Sdh2p of
the yeast mitochondrial ETC [15]. We have observed that the
single mutant for yfh1p showed regular growth in fermentative
conditions (YPD medium), whereas double mutants yfh1D sdh1D
and yfh1D sdh2D showed a poor growth in such conditions, and the
triple mutant, yfh1D sdh1D sdh2D, was even poorer (Figure 1A, left
panel). When cells were cultured in respiratory conditions
(ethanol/glycerol medium) all mutant strains including the single
mutant showed abnormal growth (Figure 1B, left panel). As FAD
is the cofactor of complex II we initially decided to investigate the
effect of FAD in mutant yeast growth. First of all, we performed a
dose-dependent study with FAD in yeast strains (Figure 2). We
used a range of different doses, between 0.1 mM to 10 mM. We
analyzed yeast growth in the yfh1D single mutant, the double
mutants yfh1D sdh1D and yfh1D sdh2D, and the triple mutant
yfh1D sdh1D sdh2D (see Supplementary Table S1), in both
fermentative and respiratory conditions. Addition of FAD to
cultures improved cell growth of single yfh1D and double mutants’
yfh1D sdh1D and yfh1D sdh2D in fermentative conditions (Figure 1A,
right panel). Interestingly, growth amelioration of the triple
mutant yfh1D sdh1D sdh2D in the presence of FAD was outstanding
(Figure 1A, right panel). Growth was also induced by FAD in
respiratory conditions (Figure 1B, right panel). Double mutants
and the triple mutant were not able to growth in ethanol/glycerol
medium and yfh1D strain grew poorly, but in all cases the growth
rate of yeast cells improved in the presence of FAD. These findings
suggest that FAD may be able to rescue the growth of the strains in
both fermentative and respiratory conditions. Then we checked
whether abnormal growth in respiratory conditions could be
rescued by addition of either riboflavin or FMN cofactor.
Riboflavin did not improve the growth of any strain (Figure 3A).
In fact, riboflavin seemed to be toxic at the concentrations we
used. By contrast, cultures in the presence of FMN improved cell
growth (Figure 3B), but using higher doses that those use for FAD.
We wonder whether the effect of the FAD was through complex
II. To answer this question we tested the growth of single mutants
sdh1D, sdh2D and the double mutant sdh1D sdh2D. In these strains,
FAD rescues the phenotype and growth perfectly in respiratory
conditions (Figure 4). These results suggest that growth recovery is
not dependent on the presence of complex II subunits Sdh1p and
Sdh2p.
FAD Cofactor Improves Activities of the ETC Complexes
Except for Complex II
To address whether this improvement is due to an effect on the
respiratory chain activity, we measured the activity of complexes I,
II, III and IV in a wild-type strain (W303) and in the single
mutants yfh1D, sdh1D, sdh2D, and ypr004cD (the yeast homologue
of the mammalian electron transfer flavoprotein a gene, ETFa).
The frataxin mutant showed a significantly decreased activity in
every complex except for complex I (Figure 5A). Both sdh1D and
sdh2D strains showed abnormal activities for complex II and
complexes II+III. As expected, the absence of ypr004c gene did not
affect any enzymatic activity of the ETC. Thus, we proceeded to
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investigate the effect of FAD in ETC complexes activities in
ethanol/glycerol medium that forces yeast to respire. Since the
growth response of the mutant strain to FAD had not been dose
dependent and ETC measures were performed on mitochondrial
extracts from yeast cells grown in liquid medium, we decided to
use the higher dose, 10 mM. We found an improvement of every
complex activity in the wild-type. Interestingly, in the yfh1D
mutant we observed a significant amelioration of complex I,
complex III, complex IV and complex I+III activities but not in
complex II and complex II+III activities (Figure 5B). Thus, FAD
increases the activity in every complex except complex II. This
result confirms the observation that FAD effect on growth
improvement of frataxin-deficient cells is acting independently of
complex II.
Figure 2. Dose-response analysis of FAD supplementation. A) Serial dilutions of cell suspensions of the different strains were spotted on YPD
medium supplemented with increasing concentrations of FAD and incubated at 30uC for 48 hours. B) The wild-type and mutants’ strains were also
spotted in ethanol/glycerol medium supplemented with increasing concentrations of FAD and incubated at 30uC for 48 hours.
doi:10.1371/journal.pone.0008872.g002
Figure 1. Analysis of the yeast growth. Serial dilutions of cell suspensions of the different strains were spotted on either YPD rich medium or
ethanol/glycerol medium and incubated at 30uC for 48 hours. A) Cells grown on rich YPD plates with or without 0.1 mM FAD supplementation. B)
Cells were grown on synthetic ethanol/glycerol medium plates with or without 0.1 mM FAD supplementation.
doi:10.1371/journal.pone.0008872.g001
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FAD Cofactor Increases the Production of ATP in Frataxin
Mutant
To know the effect of improvement of ETC activities in the
oxidative phosphorylation we measured ATP production in
respiratory conditions. When adding FAD to wild-type cells we
observed an increase of ATP production that correlated with
increased activities of ETC complexes. In such conditions only
wild-type cells showed a good growth; by contrast, yfh1D grew
very poorly. However, addition of FAD not only induced cell
growth but also increased ATP production even to higher levels
that of wild-type yeast (Figure 6).
Alternative Pathways for FAD Action
To know about the action of FAD on ETC and OXPHOS
activities in an independent manner of complex II we investigate
the effect of the cofactor on the Etf complex. We performed
growth experiments under respiratory conditions in mutant strains
for putative Etfa subunit, ypr004c, of the Etf complex (Figure 7).
Although ypr004cD strain could grow under respiratory conditions
it strongly ameliorated when FAD was added to the culture; yfh1D
ypr004cD double mutant grew poorer than the single ypr004cD
strain but it was also rescued by FAD, as we previously had
observed for the yfh1D sdh1D and yfh1D sdh2D mutants. To know if
the FAD effect depends on the presence of at least one of yfh1, sdh
or ypr004c genes we analyzed yeast growth of the yfh1D sdh1D
ypr004cD strain. The triple mutant strain did not grow under
respiratory conditions but growth was partially rescued when
adding FAD. Altogether, these findings suggest that the biological
action of FAD on yeast growth do not exclusively depend on the
presence of these three genes.
FAD and FMN, but Not Riboflavin, Partially Rescue the
Phenotype in Frataxin-Deficient Worms
The previous results clearly show that both FAD and FMN
rescue the deficiency of frataxin in S. cerevisiae. To find out if these
flavins could be developed as potential therapeutic agents, it would
be interesting to show that they can also act in the same fashion in a
multicellular organism such us C. elegans. Experiments were
performed in transient knock-down worms (frh-1[RNAi]) generated
by microinjection of dsRNA frh-1 into gonads of adult worms. The
F1 progeny of injected nematodes show a pleiotropic phenotype
when compared with controls (Figure 8A) which includes pale body
colour and reduced number of eggs within the worm (Figure 8B),
thin morphology, reduced lifespan, reduced brood size, altered
defecation, and increased sensitivity to oxidative stress [33].
We analyzed morphological appearance and physiological
parameters in five-day-old frh-1[RNAi] worms growing in plates
with riboflavin or riboflavin-derived cofactors. We observed an
evident increase in the worm size with either FAD or FMN.
Worms seemed to be healthier, to lay more eggs and to improve
the egg development (Figures 8C and 8D). Worms supplemented
with FAD improved their fertility as well as we observed increased
number of eggs and larvae compared with frh-1[RNAi] control
worms (data not shown). By constrast, riboflavin addition did not
improve the knock-down phenotype.
Figure 3. Dose-response analysis of riboflavin and FMN supplementation. Serial dilutions of cell suspensions of the different strains were
spotted on in ethanol/glycerol medium supplemented with increasing concentrations of riboflavin (A) and FMN (B), and incubated at 30uC for
48 hours.
doi:10.1371/journal.pone.0008872.g003
Figure 4. Analysis of the effect of FAD on sdh1D and sdh2D cells
growth. Serial dilutions of cell suspensions of the different strains were
spotted on the indicated media and incubated at 30uC for 48 hours.
Cells were grown on synthetic ethanol/glycerol medium plates
supplemented with 0.01 mM FAD.
doi:10.1371/journal.pone.0008872.g004
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FAD and FMN Increase Lifespan, Fertility and Defecation
Rhythm in Knock-Down Worms
frh-1[RNAi] worms show a pleiotropic phenotype and physio-
logical behaviour that include reduced longevity, uncoordinated
pharynx pumping, egg laying defects (Egl phenotype), lower
number of eggs within the uterus, reduced brood size and
abnormal defecation rate [33]. Thus, we investigated the effect of
flavins in the lifespan, egg laying and defecation of frh-1[RNAi]
nematodes. Lifespan was determined by counting the number of
days from the first larval stage (L1) until the worm died. We
analyzed approximately 40 worms for each drug, and the
experiment was performed twice. Lifespan is significantly
recovered in all conditions (FAD, p,0.01; FMN, p,0.01;
riboflavin, p,0.01) (Figure 9A). Half lifespan for control
Figure 5. Enzymatic activity analysis of the ETC in yeast mitochondria. A) Wild-type, yfh1D, sdh1D, sdh2D, ypr004cD cells were grown in YPD
media under aerobic conditions until exhaustion of the carbon source. Mitochondria were isolated and used to determine the enzymatic activity of
the complex I, II, III, IV, I+II and I+III of the respiratory chain. Errors bars indicate the standard deviation of at least three independent measurements.
(t-Student, *p,0.05; **p,0.01). B) Analysis of addition of FAD on ETC complexes activities. FAD increases the activity of ETC complexes. Wild-type
and yfh1D cells were grown in ethanol/glycerol medium with 10 mM FAD in aerobic conditions. Mitochondria were isolated and used to determine
the enzymatic activity of the complex I, II, III, IV, I+II and I+III of respiratory chain. No histogram is indicated for yfh1D cells with any FAD addition
because they did not grow on ethanol/glycerol medium. Errors bars indicate the standard deviation of at least three independent assays.
doi:10.1371/journal.pone.0008872.g005
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cat[RNAi] worms was 15.562.9 days, and decreased to 1162.3
days for frh1[RNAi] individuals. FAD increased half lifespan to
1864.6 days, that is, seven days more than the frataxin-deficient
worms, whereas the increased lifespan with either FMN or
riboflavin was lower but still significant.
To study fertility we counted the eggs laid by each worm in
individual plates and moved to fresh plates every eight hours. We
observed that brood size was recovered after addition of with FAD
(p= 0.01) or FMN (p= 0.01) (Figure 9B), although values did not
reach to those of control worms. This effect agrees with the
apparent observation of the egl-1 phenotype rescue we have
observed in the frh-1[RNAi] worms after treatment.
Defecation in C. elegans is achieved by periodically activating a
stereotyped sequence of muscle contractions. Each defecation
cycle can be thought of as having three distinct steps: the posterior
body muscle contraction (pBoc), the anterior body muscle
contraction (aBoc), and the expulsion (Exp), which consists of
the intestinal muscle and anal depressor contractions. Each of
these three steps appears to be controlled by a separate set of
motor neurons, and all three steps are co-ordinately and cyclically
activated from some unidentified source [41]. Defecation in frh-
1[RNAi] worms is altered with increasing the rhythm of
defecation between consecutive pBoc contractions [33]. We
measured the interval time from pBoc to the next pBoc for 10
consecutive cycles in 10 worms, comparing frh-1[RNAi] worms
treated with flavins and frh-1[RNAi] worms with no treatment. We
observed significant recovering of defecation when adding flavins
to cultures (FAD, p,0.01; FMN p,0.01) (Figure 9C).
Discussion
We had previously showed that both yeast and human frataxins
interact with complex II subunits Sdh1p/Sdh2p and SDHA/
SDHB, respectively [15]. FAD is the prosthetic cofactor of
complex II covalently bound to the flavoprotein subunit Sdh1p/
SDHA. FAD and FMN are cofactors derived from the metabolism
of riboflavin, which has been employed in the treatment of several
disorders involving different enzymatic complexes of the OX-
PHOS system: complex I deficiency [36,42,43], complex II
deficient patients, at least by reducing the rate of disease
progression [40], and in a boy with Leigh syndrome and complex
II deficiency [44]. Response to riboflavin in patients with defects of
either b-oxidation [45,46] or single flavo-apoenzymes: pyruvate
dehydrogenase [47], electron transfer flavoprotein [48] and short-
chain acyl coenzyme A dehydrogenase [37] have been reported as
well. Riboflavin has also been used for the treatment of respiratory
chain disorders in combination with other cofactors such as
nicotinamide in patients with MELAS syndrome, having a
favourable response [49].
Thus, we hypothesized that may riboflavin and its cofactors FAD
and FMN might be good candidate drugs for FRDA therapy. To
address this point we have investigated the effect of riboflavin, FAD
and FMN in two organism models of frataxin deficiency, S. cerevisiae
and C. elegans. In both organisms we could partially rescue the
abnormal phenotype. This pharmacological effect was more evident
for FAD. We have observed that FAD improves growth of yfh1D
yeast in respiratory conditions and several physiological parameters
of frh-1[RNAi] knock-down worms, such as lifespan, fertility and
defecation. We also observed some amelioration by FMN although
it was milder than FAD. Riboflavin showed contradictory results: it
was toxic in yeast at the concentrations we used but lifespan was
increased in the knock-down worms. Specific metabolic routes for
riboflavin have been described in both organisms [50], so we suspect
that such a toxic effect in yeast may be dose-dependent [51].
Riboflavin provides FMN and FAD, which function as
coenzymes in respiratory chain complexes I and II, respectively,
but the mechanism underlying its possible efficacy in respiratory
chain disorders is still poorly understood. Different arguments
have been proposed to explain the beneficial of riboflavin
treatment. Riboflavin may act by inhibiting the proteolytic
breakdown of complex I, with a subsequent increase in enzymatic
activity [52,53]. On the other hand, riboflavin supplementation
could exert a general stabilizing effect on the assembly and correct
functioning of mitochondrial flavin-dependent complexes I and II,
generating a positive functional effect on the catalytic activity.
In the case of frataxin deficiency we hypothesized that riboflavin
may provide FAD molecules to complex II improving energetic
metabolism by addressing electrons towards CoQ. However, while
growth recovery of yfh1D could be explained by this way growth
recovery of both Sdh1D and Sdh2D strains does not agree with such
a postulate as the appropriate structure of complex II in these
mutants is defective. The observed growth amelioration of these
mutant yeast strains should depend on other biochemical routes.
Since both ETF heterodimer and ETF-QO have FAD as a
Figure 6. Analysis of the ATP synthesis in yeast mitochondria.
ATP production was greater in cells grew with FAD. Wild-type and
yfh1D cells were grown in ethanol/glycerol medium under aerobic
conditions with or without 10 mM FAD. No histogram is indicated for
yfh1D cells with any FAD addition because they did not grow on
ethanol/glycerol medium. Mitochondria were isolated and used to
determine ATP production using the Adenosine 59-triphosphate (ATP)
Bioluminescent Assay Kit as indicated by the manufacturer. Errors bars
indicate the standard deviation of at least three independent assays.
doi:10.1371/journal.pone.0008872.g006
Figure 7. Analysis of the effect of FAD on ypr004cD cells growth.
Serial dilutions of cell suspensions of the different strains were spotted
on the indicated media and incubated at 30uC for 48 hours. Cells were
grown on synthetic ethanol/glycerol medium plates supplemented
with 0.01 mM FAD.
doi:10.1371/journal.pone.0008872.g007
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prosthetic group we hypothesized that ETF complex may be a
candidate for FAD action. ETF serves as an electron acceptor for
the acyl-CoA dehydrogenases involved in fatty acid oxidation as
well as for several dehydrogenases involved in amino acid and
choline metabolism. Subsequently, these electrons are transferred
via ETF-QO to CoQ in the respiratory chain. Thus, we
introduced the putative yeast gene for Etfa, ypr004c, in our
analysis. Yeast cells defective for ypr004c showed almost normal
growth in respiratory conditions and normal enzymatic activities
of ETC complexes in fermentative conditions. Single mutants for
yfh1, sdh1, sdh2 or ypr004c responded to FAD when growing cells in
respiratory conditions. Even double mutants of yfh1 with sdh1, sdh2
or ypr004c respond to FAD as well. To observe much reduced
response to FAD all three genes, yfh1, sdh1 and ypr004c should be
deleted in yeast cells but in such conditions some growth is still
observed. These results may be interpret as FAD is acting via
complex II and Etf complex but at least another route still remain
relevant. This route may be via complex I that remain unaffected
in yeast cells defective for yfh1. Supporting this is the fact that FAD
strongly increase complex I activity of the yfh1D cells in respiratory
conditions. Based on our results we suggest that riboflavin may be
useful in the treatment of Friedreich ataxia patients as in other
OXPHOS disorders.
Materials and Methods
Strains
Strains used in this study are listed in Supplementary Material,
Table S1.
Phenotypic Analyses in Yeast
The effect of riboflavin and riboflavin derivatives (FMN and
FAD) on mutants was assessed by growing the strains in rich (YPD;
yeast extract, peptone, dextrose) and ethanol-glycerol medium.
Previously, cells growing exponentially in YPD medium were
harvested and adjusted to 0.1 units of absorbance at 600 nm.
Serial dilutions were made with sterile water and 3 ml of each
dilution was spotted on the different culture media and different
riboflavin concentrations (0.01 mM, 0.1 mM, 0.5 mM, 1 mM),
FMN (0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM) and FAD
(0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM). Plates were incubated at
30uC for 48 hours.
Obtaining Crude Mitochondria
Wild-type, yfh1D, sdh1D, sdh2D and ypr004cD strains were grown
in rich medium (YPD; yeast extract, peptone, dextrose). Wild-type
and yfh1D cells were grown in ethanol/glycerol medium with
10 mM FAD in aerobic conditions and only wild-type in ethanol/
glycerol medium without FAD. Isolation of yeast mitochondria
was as described [54], and were used for assays of ETC enzymatic
activities.
Mitochondrial Respiratory Chain Activities
Freshly obtained mitochondria were assayed for complex I,
complex II, complex III, complex IV, complex I+II and complex
II+III activities. All assays were performed in triplicate at 30uC
with stirring. In all the reactions mitochondrial protein (10–60 mg)
was incubated in reaction buffer (40 mM sodium phosphate,
pH 7.4) for 1 min.
Figure 8. Phenotypic analysis of frh-1[RNAi] worms. Nomarski photographs show worms of 5 days-old cultured at 20uC.A) cat[RNAi] worm as a control
showing normal morphology. B) frh-1[RNAi] worm showing thinner morphology, pale body and fewer eggs into the worm. C) frh-1[RNAi] worm incubated in
NGM agar supplemented with 0.5 mM FMN. Treated frh-1[RNAi] worms show increase in the number of eggs when comparing with not treated knock-down
worms (figure 6B). We observed general improvement in the phenotype. D) Comparison of the morphology of frh-1[RNAi] worms supplemented with 5 mM
FAD (top) or with no drug supplementation (bottom); the worm grown in the supplemented medium was less thin and morphology was improved.
doi:10.1371/journal.pone.0008872.g008
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Complex I. The reaction was initiated with 75 mM DCIP,
without NADH; after 1 min, 200 mM NADH was added. Specific
activity of DCIP reduction was determined at 600 nm with an
extinction coefficient of 19.1 mM21 cm21.
Complex II. The reaction was initiated with the addition of
250 mM potassium cyanide and 75 mM DCIP; after 1 min,
40 mM sodium succinate was added. Reactions were monitored
via spectrophotometric measurements of absorbance at 600 nm.
The specific activity was determined with an extinction coefficient
of 19.1 mM21 cm21.
Complex III. The reaction was initiated with the addition of
250 mM potassium cyanide and 100 mM cytochrome c; after
1 min, 50 mM decylubiquinone was added. The reaction was
monitored via spectrophotometric measurements of absorbance at
550 nm. Specific activity was determined with an extinction
coefficient of 19.5 mM21 cm21.
Complex IV. The reaction was initiated with the addition of
100 mM cytochrome c reduce with ascorbate. The reaction was
monitored via spectrophotometric measurements of absorbance at
550 nm. Specific activity was determined with an extinction
coefficient of 19.5 mM21 cm21.
Complex I+III. The reaction was initiated with the addition
of 250 mM potassium cyanide and 100 mM cytochrome c; after
1 min, 100 mM NADH was added. The reaction was monitored
via spectrophotometric measurements of absorbance at 550 nm.
Specific activity was determined with an extinction coefficient of
19.5 mM21 cm21.
Complex II+III. The reaction was initiated with the addition
of 250 mM potassium cyanide and 100 mM cytochrome c; after
1 min, 40 mM sodium succinate was added. The reaction was
monitored via spectrophotometric measurements of absorbance at
550 nm. Specific activity was determined with an extinction
coefficient of 19.5 mM21 cm21.
ATP Assays
Mitochondrial concentrations of ATP were determined using
the Adenosine 59-triphosphate (ATP) Bioluminescent Assay Kit
(Sigma) following the manufacturer’s instructions.
Figure 9. Lifespan and other physiological parameters analyses of frh-1[RNAi] nematodes. A) Worms were transferred into fresh NGM
plates supplemented with FAD, FMN or riboflavin at 20uC from larval stage L1 until they died. These worms were compared with frh-1[RNAi] worms
grew without cofactors and with cat[RNAi] worms as a negative control. B) Proportion of dead embryos was determined in frh-1[RNAi] worms treated
with FAD, FMN and riboflavin at 20uC. Five worms were analyzed for each drug. These worms were compared with frh-1[RNAi] worms grew without
cofactors and with cat[RNAi] worm as a negative control. Histograms show means 6 SEM. C) Analysis of defecation in frataxin deficient frh-1[RNAi]
worms. Defecation interval represents the mean between two pBoc contractions and shows significant differences among frh-1[RNAi] worms and frh-
1[RNAi] worms supplemented with FAD (p,0.01) and FMN (p,0.01). cat[RNAi] worm as a negative control. Histograms show means 6 SEM.
doi:10.1371/journal.pone.0008872.g009
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Strain and Worm Culture
We used the C. elegans strain Bristol N2, which was supplied by
the Caenorhabditis Genetics Centre (University of Minnesota, MN).
Worms were maintained on nematode growth medium (NGM)
with Escherichia coli strain OP50 [55] and supplemented with
riboflavin or its cofactors when appropriate. Standard supplemen-
tation experiments were performed with 0.5 mM riboflavin, 5 mM
FAD or 0.5 mM FMN. Worms were incubated at 20uC and the
progeny was analyzed.
RNA Interference
RNAi in C. elegans was performed as described previously
elsewhere [33].
Phenotypic and Physiological Assays in C. elegans
We compared frh-1[RNAi] worms treated with drugs and frh-
1[RNAi] worms without drugs by analyzing brood size of F2,
lifespan and defecation. We observed the morphology under optic
microscope of worms of five years old after hatching. They were
immobilized with 10 mM levamisole and were mounted on pads
with M9 buffer to avoid desiccation. To determine the lifespan,
approximately 40 hermaphrodite worms were transferred into
fresh NGM plates at 20uC until they died. Nematodes were
transferred into new plates during the experiments to avoid mixing
tested worms with their offspring. The viability of adult animals
was checked under a stereomicroscope everyday and when they
did not move after touching with a platinum wire they were
considered as dead. The size of F2 offspring was assessed by
placing a single worm on individual NGM plates supplemented
with drugs at 20uC, moving it every eight hours and counting the
eggs laid. Five worms were analyzed for each drug. Defecation
cycles were analyzed by observation of L4 larvae under the
stereomicroscope, measuring the time from pBoc to next pBoc.
For each drug, ten worms were followed for ten continuous
defecation cycles at 20uC.
Statistical Analysis
Data are expressed as mean 6 SEM. For lifespan analysis, data
were compared by log rank Mantel-Cox test statistical analysis.
The Mann-Whitney test was used for statistical analysis of F2
brood-size and defecation. Statistic significance for enzymatic
activities of the mitochondrial respiratory chain complexes was
determined by Student’s t test. p,0.05 was considered significant.
Supporting Information
Table S1 Saccharomyces cerevisiae strains used in this study
Found at: doi:10.1371/journal.pone.0008872.s001 (0.06 MB
DOC)
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